Edwards Lifesciences (EW) has reported Q2 2026 results with total revenue of US$1,741 million and basic EPS of US$0.42, while trailing twelve month revenue stands at US$6.5 billion with EPS of US$1.69 as the company works through a period of softer profitability. The company has seen quarterly revenue move from US$1,532 million in Q2 2025 to US$1,741 million in Q2 2026, with basic EPS shifting from US$0.58 to US$0.42 over the same period as trailing net margin compressed from 24.8% to 15% and a US$640.7 million one off loss weighed on reported earnings, which is likely to prompt investors to pay close attention to how margin trends align with expectations for future growth.

See our full analysis for Edwards Lifesciences.

With the latest results on the table, the next step is to see how these revenue, EPS and margin trends line up against the widely followed narratives around Edwards Lifesciences’s growth potential and risk profile.

See what the community is saying about Edwards Lifesciences

Margins Under Pressure From One Off Loss

• Trailing 12 month net profit margin is 15%, down from 24.8% a year earlier, with a US$640.7 million one off loss weighing on reported profitability over the period.
• Bears highlight that a 15% margin and the impact of tariffs and JenaValve related EPS dilution could keep pressure on Edwards Lifesciences, yet
  • the consensus narrative also points to planned tariff mitigation and cost control efforts that are aimed at supporting earnings even as expenses for R&D and acquisitions rise, and
  • management’s plan to offset an expected EPS impact of US$0.05 in 2025 and a further US$0.05 to US$0.10 from JenaValve shows how much of the current margin picture is tied to specific, identified headwinds rather than everyday operations.

For investors worried about whether these margin pressures justify caution, it is worth reading how skeptics frame the risks in the latest bear case for Edwards Lifesciences 🐻 Edwards Lifesciences Bear Case.

Revenue Rising While EPS Stays Choppy

• Quarterly revenue moved from US$1,532.2 million in Q2 2025 to US$1,741 million in Q2 2026, while basic EPS over the same stretch ranged between US$0.11 and US$0.66 in the last four quarters, landing at US$0.42 in Q2 2026 as net income excluding extra items came in at US$241.9 million.
• Consensus narrative talks about multiyear growth from TAVR, EVOQUE and Sapien M3, yet
  • the recent earnings path, with net income excluding extra items moving between US$64.2 million and US$380.7 million across the last five quarters, shows that earnings are not moving in a straight line even as revenue trends higher, and
  • risks around tariffs, competitive pressure in markets like Japan and higher discretionary R&D spending mean revenue traction from new therapies has to work alongside higher costs to keep EPS on track.

High P/E Meets Growth Forecasts

• At a share price of US$82.63, Edwards Lifesciences trades on a P/E of 48.6x versus peer and US Medical Equipment industry averages of 25.6x and 26.4x, while analysts expect earnings to grow about 20.2% per year over the next three years and see DCF fair value at roughly US$90.40 compared with an analyst price target of US$100.36.
• Bullish investors argue that future growth and margin expansion can justify the premium, and the numbers line up with that view in several ways,
  • with forecasts calling for profit margins to move from 17.1% to 25.9% over three years and earnings to reach about US$2.1 billion (EPS of US$3.78) by around July 2029, and
  • analysts assuming the P/E could settle near 31x on those 2029 earnings, which is lower than the current 48.6x but still above the 25.6x industry level, suggesting the current premium rests heavily on that margin and earnings path playing out.

If you want to see how those growth and valuation expectations translate into a full bullish storyline for Edwards Lifesciences, the dedicated bull case is a helpful next step 🐂 Edwards Lifesciences Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Edwards Lifesciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of concerns and optimism around Edwards Lifesciences, it makes sense to review the data for yourself and move promptly from headlines to hard numbers by weighing the 3 key rewards and 3 important warning signs.

See What Else Is Out There Beyond Edwards Lifesciences

Edwards Lifesciences is working through margin compression, choppy EPS and a premium P/E that leans heavily on forecasts, leaving some investors questioning the risk reward trade off.

If that mix of earnings volatility and rich valuation makes you hesitant, compare it with companies screened for strong valuation support and potential upside using the 49 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.